[{"id":"503fb49c-7f9c-44d3-9d06-e13901c0cc31","acronym":"","url":"https://clinicaltrials.gov/study/NCT07471815","created_at":"2026-03-28T01:43:58.232Z","updated_at":"2026-03-28T01:43:58.232Z","phase":"Phase 2","brief_title":"Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy","source_id_and_acronym":"NCT07471815","lead_sponsor":"Harbin Medical University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/04/2026","start_date":" 03/04/2026","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 03/31/2029","study_completion_date":" 03/31/2029","last_update_posted":"2026-03-13"},{"id":"ab44ad05-9bd9-4db7-9ebb-ab1b8496e06f","acronym":"","url":"https://clinicaltrials.gov/study/NCT07190027","created_at":"2025-09-27T08:39:53.097Z","updated_at":"2025-09-27T08:39:53.097Z","phase":"Phase 1/2","brief_title":"Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial","source_id_and_acronym":"NCT07190027","lead_sponsor":"First Affiliated Hospital of Wenzhou Medical University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Tyvyt (sintilimab) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 246","initiation":"Initiation: 11/01/2025","start_date":" 11/01/2025","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2028","study_completion_date":" 11/01/2028","last_update_posted":"2025-09-24"},{"id":"342c2212-312d-4751-97cb-897cdaabd015","acronym":"","url":"https://clinicaltrials.gov/study/NCT06817525","created_at":"2025-02-25T15:38:27.775Z","updated_at":"2025-02-25T15:38:27.775Z","phase":"Phase 2","brief_title":"Nab-P+Cb+PD1 Inhibitors Combined/not Combined with Bevacizumab As Neoadjuvant Therapy for Early TNBC","source_id_and_acronym":"NCT06817525","lead_sponsor":"Henan Cancer Hospital","biomarkers":" CD8 • PD-1 • VEGFA • CD4 • FGF • GZMB • TGFB1 • CD31 • PECAM1","pipe":"","alterations":" ","tags":["CD8 • PD-1 • VEGFA • CD4 • FGF • GZMB • TGFB1 • CD31 • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carboplatin • AiRuiKa (camrelizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 11/06/2024","start_date":" 11/06/2024","primary_txt":" Primary completion: 11/06/2025","primary_completion_date":" 11/06/2025","study_txt":" Completion: 11/06/2025","study_completion_date":" 11/06/2025","last_update_posted":"2025-02-10"},{"id":"69217ac1-4fa4-4e9f-9c24-69f00b5e6dcc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05937438","created_at":"2023-07-10T13:08:45.201Z","updated_at":"2025-02-25T17:39:00.933Z","phase":"Phase 1/2","brief_title":"Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma","source_id_and_acronym":"NCT05937438","lead_sponsor":"Anhui Provincial Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-01-29"},{"id":"5ab5758f-ded0-479b-83dd-b16b495d0f1a","acronym":"FASCINATE-N","url":"https://clinicaltrials.gov/study/NCT05582499","created_at":"2022-10-17T13:56:00.115Z","updated_at":"2025-02-25T12:29:07.250Z","phase":"Phase 2","brief_title":"Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy","source_id_and_acronym":"NCT05582499 - FASCINATE-N","lead_sponsor":"Fudan University","biomarkers":" HER-2 • PGR • CD8 • FOXC1","pipe":"","alterations":" ","tags":["HER-2 • PGR • CD8 • FOXC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • Perjeta (pertuzumab) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Irene (pyrotinib) • albumin-bound paclitaxel • cyclophosphamide • letrozole • epirubicin • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020) • AiRuiLi (adebrelimab) • tizetatug rezetecan (SHR-A1921)"],"overall_status":"Recruiting","enrollment":" Enrollment 716","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-12-27"},{"id":"1eeb0f08-7927-4438-a063-9e9859dc3e24","acronym":"","url":"https://clinicaltrials.gov/study/NCT06516289","created_at":"2025-02-26T10:01:45.127Z","updated_at":"2025-02-26T10:01:45.127Z","phase":"Phase 2","brief_title":"Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab","source_id_and_acronym":"NCT06516289","lead_sponsor":"Fudan University","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • famitinib (SHR 1020) • M9466"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 09/30/2024","start_date":" 09/30/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-12-12"},{"id":"6ca03c28-cf88-4ab8-8a2b-e94506f71d40","acronym":"","url":"https://clinicaltrials.gov/study/NCT04701060","created_at":"2025-02-26T10:39:27.170Z","updated_at":"2025-02-26T10:39:27.170Z","phase":"Phase 2","brief_title":"Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma","source_id_and_acronym":"NCT04701060","lead_sponsor":"Tianjin Medical University Cancer Institute and Hospital","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • AiTan (rivoceranib)"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 01/26/2021","start_date":" 01/26/2021","primary_txt":" Primary completion: 03/04/2024","primary_completion_date":" 03/04/2024","study_txt":" Completion: 10/04/2024","study_completion_date":" 10/04/2024","last_update_posted":"2024-12-03"},{"id":"1455a292-12e3-4ee4-837b-54ea7dad02d1","acronym":"","url":"https://clinicaltrials.gov/study/NCT06533384","created_at":"2025-02-27T07:58:59.217Z","updated_at":"2025-02-27T07:58:59.217Z","phase":"Phase 3","brief_title":"PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC","source_id_and_acronym":"NCT06533384","lead_sponsor":"Guangdong Provincial People's Hospital","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • capecitabine • AiRuiYi (fluzoparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 310","initiation":"Initiation: 08/01/2024","start_date":" 08/01/2024","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2024-11-04"},{"id":"ce949133-11a2-485d-8894-d641efac89fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT06591078","created_at":"2025-02-26T14:52:39.369Z","updated_at":"2025-02-26T14:52:39.369Z","phase":"","brief_title":"Evaluation of Clinical Efficacy of Acupuncture in Improving Immune Response in Patients With Cervical Cancer","source_id_and_acronym":"NCT06591078","lead_sponsor":"Ying Zhang","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 09/15/2024","start_date":" 09/15/2024","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-09-19"},{"id":"536366b3-1ab0-4236-bee6-169337ebf109","acronym":"","url":"https://clinicaltrials.gov/study/NCT06413992","created_at":"2024-05-18T04:21:52.082Z","updated_at":"2024-07-02T16:35:03.774Z","phase":"Phase 2","brief_title":"Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer","source_id_and_acronym":"NCT06413992","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" PD-L1 • HRD","pipe":" | ","alterations":" HRD","tags":["PD-L1 • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • AiRuiKa (camrelizumab) • albumin-bound paclitaxel • AiRuiYi (fluzoparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 117","initiation":"Initiation: 05/10/2024","start_date":" 05/10/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-05-14"},{"id":"5d93f81b-6363-4cfb-8546-e62fcaccc6be","acronym":"NEOPBOSCC","url":"https://clinicaltrials.gov/study/NCT04649476","created_at":"2024-04-12T13:44:42.720Z","updated_at":"2024-07-02T16:35:09.900Z","phase":"Phase 2","brief_title":"Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma","source_id_and_acronym":"NCT04649476 - NEOPBOSCC","lead_sponsor":"Hospital of Stomatology, Wuhan University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • docetaxel • 5-fluorouracil • AiRuiKa (camrelizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 03/22/2021","start_date":" 03/22/2021","primary_txt":" Primary completion: 08/10/2022","primary_completion_date":" 08/10/2022","study_txt":" Completion: 08/10/2024","study_completion_date":" 08/10/2024","last_update_posted":"2024-04-12"},{"id":"8376cad8-b86a-4e59-8de8-f0511fd2d60b","acronym":"NEOPCOSCC","url":"https://clinicaltrials.gov/study/NCT05798793","created_at":"2024-02-05T15:19:44.475Z","updated_at":"2024-07-02T16:35:11.846Z","phase":"Phase 3","brief_title":"Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma","source_id_and_acronym":"NCT05798793 - NEOPCOSCC","lead_sponsor":"Hospital of Stomatology, Wuhan University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • docetaxel • AiRuiKa (camrelizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 309","initiation":"Initiation: 11/21/2023","start_date":" 11/21/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-04-02"},{"id":"b3d1f112-0e04-4d4b-9834-315e4294e693","acronym":"","url":"https://clinicaltrials.gov/study/NCT04674956","created_at":"2024-04-02T20:40:59.614Z","updated_at":"2024-07-02T16:35:11.876Z","phase":"Phase 3","brief_title":"A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer","source_id_and_acronym":"NCT04674956","lead_sponsor":"RenJi Hospital","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • paclitaxel • AiRuiKa (camrelizumab) • albumin-bound paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 401","initiation":"Initiation: 03/04/2021","start_date":" 03/04/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-04-02"},{"id":"c78fd3b4-542c-4f48-8407-31637e45046d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04613674","created_at":"2021-01-19T20:33:05.685Z","updated_at":"2024-07-02T16:35:12.673Z","phase":"Phase 3","brief_title":"A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)","source_id_and_acronym":"NCT04613674","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression • PGR expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab)"],"overall_status":"Completed","enrollment":" Enrollment 441","initiation":"Initiation: 12/09/2020","start_date":" 12/09/2020","primary_txt":" Primary completion: 09/14/2023","primary_completion_date":" 09/14/2023","study_txt":" Completion: 03/05/2024","study_completion_date":" 03/05/2024","last_update_posted":"2024-03-27"},{"id":"a548212c-cd9c-41ca-9547-6e16050ba508","acronym":"","url":"https://clinicaltrials.gov/study/NCT05862064","created_at":"2023-05-17T14:05:17.924Z","updated_at":"2024-07-02T16:35:13.220Z","phase":"Phase 3","brief_title":"PD-1 Combined With Adjuvant Chemotherapy and Antivascular Therapy Versus Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer","source_id_and_acronym":"NCT05862064","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • AiRuiKa (camrelizumab) • cyclophosphamide • epirubicin"],"overall_status":"Recruiting","enrollment":" Enrollment 606","initiation":"Initiation: 06/01/2023","start_date":" 06/01/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2024-03-22"},{"id":"380b8c39-16b7-492c-b797-7b1071a9da8a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06032052","created_at":"2023-09-11T16:10:41.127Z","updated_at":"2024-07-02T16:35:14.742Z","phase":"Phase 2","brief_title":"Single-drug Chemotherapy Plus Immunotherapy in Metastatic Non-small Cell Lung Cancer Elderly Patients","source_id_and_acronym":"NCT06032052","lead_sponsor":"Hubei Cancer Hospital","biomarkers":" EGFR • PD-L1 • ALK • ROS1 • PD-1","pipe":" | ","alterations":" PD-L1 expression","tags":["EGFR • PD-L1 • ALK • ROS1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • paclitaxel • Tyvyt (sintilimab) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr)"],"overall_status":"Recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 02/01/2024","start_date":" 02/01/2024","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-03-15"},{"id":"a1438115-0296-456a-a641-09eb7abf6714","acronym":"NACI-CERV-005","url":"https://clinicaltrials.gov/study/NCT06289062","created_at":"2024-03-01T15:32:30.149Z","updated_at":"2024-07-02T16:35:16.839Z","phase":"Phase 2","brief_title":"Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer","source_id_and_acronym":"NCT06289062 - NACI-CERV-005","lead_sponsor":"Tongji Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • AiRuiKa (camrelizumab) • albumin-bound paclitaxel"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 03/01/2024","start_date":" 03/01/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2024-03-01"},{"id":"5fb63abc-2cbd-4f1c-beb3-437e6304bfe3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03950271","created_at":"2021-01-18T19:26:38.727Z","updated_at":"2024-07-02T16:35:17.348Z","phase":"Phase 2","brief_title":"SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma","source_id_and_acronym":"NCT03950271","lead_sponsor":"Henan Cancer Hospital","biomarkers":" HER-2 • PD-L1 • MSI","pipe":"","alterations":" ","tags":["HER-2 • PD-L1 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • AiRuiKa (camrelizumab) • capecitabine • oxaliplatin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 01/20/2020","start_date":" 01/20/2020","primary_txt":" Primary completion: 01/31/2024","primary_completion_date":" 01/31/2024","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-02-28"},{"id":"f2b60ad6-b3f3-46d8-91bc-2ccd96b67058","acronym":"YOUNGBC-11","url":"https://clinicaltrials.gov/study/NCT04537286","created_at":"2021-01-18T21:42:52.302Z","updated_at":"2024-07-02T16:35:17.562Z","phase":"Phase 2","brief_title":"First-line Nab-paclitaxel Plus Cisplatin Plus Carilizumab in mTNBC Patients","source_id_and_acronym":"NCT04537286 - YOUNGBC-11","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • AiRuiKa (camrelizumab) • albumin-bound paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 08/25/2020","start_date":" 08/25/2020","primary_txt":" Primary completion: 09/15/2024","primary_completion_date":" 09/15/2024","study_txt":" Completion: 10/15/2024","study_completion_date":" 10/15/2024","last_update_posted":"2024-02-26"},{"id":"fc19fd8b-e7bb-42ac-a2ee-1c0a25c66b31","acronym":"","url":"https://clinicaltrials.gov/study/NCT05999149","created_at":"2023-08-21T16:09:23.150Z","updated_at":"2024-07-02T16:35:18.282Z","phase":"Phase 3","brief_title":"A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)","source_id_and_acronym":"NCT05999149","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression • PGR expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • AiRuiKa (camrelizumab) • albumin-bound paclitaxel • famitinib (SHR 1020)"],"overall_status":"Recruiting","enrollment":" Enrollment 424","initiation":"Initiation: 08/20/2023","start_date":" 08/20/2023","primary_txt":" Primary completion: 08/30/2025","primary_completion_date":" 08/30/2025","study_txt":" Completion: 08/30/2027","study_completion_date":" 08/30/2027","last_update_posted":"2024-02-21"},{"id":"b1dc5803-3a3c-484f-a5f9-c84389621cfd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04694183","created_at":"2021-01-19T20:49:14.341Z","updated_at":"2024-07-02T16:35:20.387Z","phase":"Phase 2","brief_title":"The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer","source_id_and_acronym":"NCT04694183","lead_sponsor":"Quan Wang","biomarkers":" HER-2 • PD-L1 • MSI","pipe":" | ","alterations":" MSI-H/dMMR • HER-2 negative","tags":["HER-2 • PD-L1 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • AiRuiKa (camrelizumab) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 08/17/2020","start_date":" 08/17/2020","primary_txt":" Primary completion: 05/06/2023","primary_completion_date":" 05/06/2023","study_txt":" Completion: 05/06/2023","study_completion_date":" 05/06/2023","last_update_posted":"2024-02-07"},{"id":"47481f7c-4d73-4ee0-9312-6b63c4d1442d","acronym":"BCTOP-L-M05","url":"https://clinicaltrials.gov/study/NCT05594095","created_at":"2022-10-26T13:56:12.698Z","updated_at":"2024-07-02T16:35:20.799Z","phase":"Phase 2","brief_title":"SNF Platform Study of HR+/ HER2-advanced Breast Cancer","source_id_and_acronym":"NCT05594095 - BCTOP-L-M05","lead_sponsor":"Fudan University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • HER-2 amplification • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 amplification • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • everolimus • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • capecitabine • albumin-bound paclitaxel • fulvestrant • exemestane • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020)"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 12/30/2022","start_date":" 12/30/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-02-06"},{"id":"99d83691-ba98-4e13-a850-14591cdf2f94","acronym":"BCTOP-T-M02","url":"https://clinicaltrials.gov/study/NCT05760378","created_at":"2023-03-08T17:01:48.152Z","updated_at":"2024-07-02T16:35:20.795Z","phase":"Phase 3","brief_title":"Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.","source_id_and_acronym":"NCT05760378 - BCTOP-T-M02","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression • PGR expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • AiRuiKa (camrelizumab) • capecitabine • Halaven (eribulin mesylate) • famitinib (SHR 1020)"],"overall_status":"Recruiting","enrollment":" Enrollment 223","initiation":"Initiation: 03/17/2023","start_date":" 03/17/2023","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-02-06"},{"id":"f56b977b-9d2c-4be8-bb3f-191550b47d48","acronym":"FUTURE-SUPER","url":"https://clinicaltrials.gov/study/NCT04395989","created_at":"2021-01-18T21:12:49.296Z","updated_at":"2024-07-02T16:35:25.372Z","phase":"Phase 2","brief_title":"An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.","source_id_and_acronym":"NCT04395989 - FUTURE-SUPER","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression • PGR expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • everolimus • AiRuiKa (camrelizumab) • capecitabine • Irene (pyrotinib) • albumin-bound paclitaxel • famitinib (SHR 1020) • Airuituo (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 139","initiation":"Initiation: 07/28/2020","start_date":" 07/28/2020","primary_txt":" Primary completion: 05/31/2023","primary_completion_date":" 05/31/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-12-22"}]